secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0000950170-24-043776
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical cuts Q1 2024 revenue guidance to $11.0-$11.3M from prior $14.8-$15.6M
--------------------------------------------------------------------------------

- Expected Q1 commercial revenue $11.0M-$11.3M vs prior guidance $14.8M-$15.6M.
- Full-year 2024 revenue guidance reaffirmed at lower end of $78.5M-$84.5M.
- Slower new account conversion: 73 accounts added since June 2023 vs expected 135 by March 2024.
- Launched PermeaDerm in March; RECELL GO launch upcoming.
- Q1 2024 earnings call scheduled for May 13, 2024 after market close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024043776/0000950170-24-043776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024043776/rcel-20240410.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-043776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer